Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894130 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL950218 | 0.83 | LMNA (0.73) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| Ethane SCHEMBL3957942 | 0.82 | SMN1; SMN2 (0.92) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| SCHEMBL29799007 | 0.81 | SMN1; SMN2 (0.70) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| SCHEMBL29412848 | 0.81 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| SCHEMBL353141 | 0.81 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| SCHEMBL30792459 | 0.81 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| SCHEMBL17180592 | 0.81 | LMNA (0.70) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL105459 | 0.81 | SMN1; SMN2 (0.70) | LMNASMN1; SMN2ALDH1A1POLBEGFR | |
| SCHEMBL15197116 | 0.79 | LMNA (0.49) | LMNASMN1; SMN2HTTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611802-B | Synthetic method of 3-acetyl-2-chloropyridine | 北京迪泰医药科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115611802-A | Synthetic method of 3-acetyl-2-chloropyridine | 北京迪泰医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-110117246-A | A kind of preparation method of 3- indoles pimelie kelone compounds | 山西大学 | 2019-08-13 | — | — | CN | claimed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025245127-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4649077-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | Cerevel Therapeutics, LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250195445-A1 | LONG-LASTING ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE AGENTS AND ANIONIC EXCIPIENTS AND USES | UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG (BR) | 2025-06-19 | — | — | US | disclosed |
| US-5541215-A | ANTIRETROVIRAL COMPOUNDS; TREATING HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-07-30 | — | — | US | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| US-5480997-A | VIRICIDE FOR HIV | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-01-02 | — | — | US | disclosed |
| EP-0672042-A1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009851-A1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
| EP-0620811-A1 | HETEROCYCLE-SUBSTITUTED BENZYLAMINE DERIVATIVES AS ANTIRETROVIRAL COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993013069-A1 | HETEROCYCLE-SUBSTITUTED BENZYLAMINE DERIVATIVES AS ANTIRETROVIRAL COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-08 | — | — | WO | disclosed |
| US-4125618-A | Novel substituted pyridines, their preparation and pharmaceutical use | MERCK & CO., INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4060601-A | Certain lower-alkyl amino-2'-hydroxy-propoxy pyridines | MERCK & CO., INC. (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | LMNA 412/4885SMN1; SMN2 4785/4885HTT 4516/4885 |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | LMNA 2257/4885SMN1; SMN2 614/4885HTT 96/4885 |
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | LMNA 3152/4885SMN1; SMN2 1018/4885HTT 869/4885 |
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 4176/4885SMN1; SMN2 3185/4885HTT 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.